AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04836949 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Prostate Ultrasound
Description: A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
Study NCT05827159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Pill
Description: In the MAUD component, some participants will receive oral Naltrexone in the ED.
Study NCT05827159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Injection
Description: In the MAUD component, some participants will receive a dose of XR-NTX (injection) in the ED.
Study NCT05827159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview
Description: Brief Negotiation Interview (BNI) has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.
Study NCT05827159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Pill
Description: In the MAUD component, ancillary treatment with gabapentin will be provided.
Study NCT05745870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate Supplementation
Description: Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
Study NCT05745870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Creatine Monohydrate Supplementation
Description: Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
Study NCT05651945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program
Description: The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.
Study NCT05277974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj bupivicain
Description: In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given
Study NCT06310148 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The Chronic Disease Co-Care (CDCC) Pilot Scheme
Description: Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
Study NCT05122286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bailout angioplasty
Description: Use balloons or stents for bailout angioplasty
Study NCT05122286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters
Study NCT05136274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
Study NCT05395676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergame home training programme
Description: Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).
Study NCT05395676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergame home training programme
Description: Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).
Study NCT06131853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey evaluation
Description: assessment of physical activity, fatigue, fear of movement, and quality of life
Study NCT06131853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey evaluation
Description: assessment of physical activity, fatigue, fear of movement, and quality of life
Study NCT04899635 — intervention group
Intervention type: OTHER
Intervention: In-vitro contractile fatigue protocol
Description: Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.
Study NCT05494307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
Study NCT05494307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Orally danazol at a dose of 200 mg twice daily for 16 weeks
Study NCT05494307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Orally danazol at a dose of 200 mg twice daily for 16 weeks
Study NCT02018692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alga Dunaliella Bardawil powder
Description: 9 cis beta carotene rich Alga Dunaliella Bardawil powder
Study NCT02018692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alga Dunaliella Bardawil powder
Description: 9 cis beta carotene rich Alga Dunaliella Bardawil powder
Study NCT02018692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo:Starch
Description: Starch powder
Study NCT02018692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo:Starch
Description: Starch powder
Study NCT05951660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~* What is sexuality?~* How psychopharmacology influences sexuality~* What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences.
Study NCT05332496 — intervention group
Intervention type: DRUG
Intervention: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
Description: PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
Study NCT05332496 — intervention group
Intervention type: PROCEDURE
Intervention: TACE
Description: TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
Study NCT05121402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018
Description: a TYK2/JAK1 inhibitor
Study NCT05121402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a TLL018 Placebo
Study NCT04909606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-led prevention program
Description: Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)~The nurse-led prevention program will include:~1. A video explaining corticosteroids related adverse events and adequate preventive measures~2. An individual interview with the trained nurse~3. A consultation with a dietetician~4. An individual sheet summarizing appropriate non-pharmacological preventive measures for the participant~5. An individual sheet summarizing appropriate pharmacological preventive measures for the referent physician~6. Phone calls at week-12, week-24 and week-36 to ensure the appropriate implementation of preventive measures
Study NCT04909606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current care
Description: Subjects randomized to the standard of care group will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
Study NCT05381506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib and Gemox
Description: Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin
Study NCT06292078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional Skill-Building Learning Approach (ISLA)
Description: The Inclusive Skill-building Learning Approach (ISLA) is a school-wide, multi-component, instructional and restorative alternative to exclusionary discipline that begins with universal prevention grounded in positive, preventative classroom strategies for all students, and layers on additional supports for students in need.
Study NCT06286423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: Colchicine treated subjects will take 0.6mg of drug 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of drug 1x per day (or every other day if kidney disease is present) for 76 +/1 days.
Study NCT06286423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control/Placebo group
Description: Placebo treated subjects will take 0.6mg of placebo 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of placebo1x per day (or every other day if kidney disease is present) for 76 +/1 days.
Study NCT06358014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fematon (estradiol/estradiol-norethindrone acetate combination tablet package)+SSRIs
Description: In the combination group, eligible subjects will receive 1 tablet/day of estradiol/estradiol-norethindrone acetate combination tablet for 8 weeks. The estradiol/estradiol-norethindrone acetate combination tablet will be taken orally before bedtime, 1 tablet/day (trade name: Fematon, Abbott Laboratories, USA, this product is a combination package, with estradiol 1 mg in the first 14 days of each treatment cycle, and estradiol 1 mg and norethindrone acetate 10 mg in the last 14 days of each treatment cycle). This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram.
Study NCT06358014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRIs
Description: This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs. During the study, medication doses will be quantitatively adjusted based on the results of each visit assessment combined with drug concentrations.
Study NCT04797195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD-PD app with home monitoring equipment
Description: use home monitoring equipment to measure blood pressure, body weight, and dialysate fluid volume and record in CKD-PD app
Study NCT06413004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Elimination and re-introduction of CLE or COLAP positive food item(s)
Description: Elimination (4 weeks) and re-introduction (4 weeks) of all CLE or COLAP positive food item(s)
Study NCT05051956 — intervention group
Intervention type: DRUG
Intervention: Palbociclib 125mg and Ribociclib 600 mg
Description: Administration of Palbociclib or Ribociclib
Study NCT05395221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Mediation Virtual Reality App
Description: Guided Meditation Virtual Reality App uses over 40 lush environments with 30 hours of guided meditations on Anxiety, Depression, Maternity, Resilience, Sleep, or Zen and 200 relaxing audio tracks using Virtual reality.
Study NCT05749835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy
Description: After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland.
Study NCT05749835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides and conventional therapy
Description: Position of therapist: stands beside the patient, while his\\her head is cradled between your body and your right forearm (when you stand at his\\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
Study NCT05844553 — intervention group
Intervention type: DEVICE
Intervention: Measurement of inhaled measuring hydrogen peroxide in exhaled breath
Description: Participant exhales in to device
Study NCT04514302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
Study NCT04514302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)
Description: INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.
Study NCT05861622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: The test product is a novel moisturizer, that contains active ingredients, including rambutan extract, niacinamide, and glycoin.
Study NCT05351918 — intervention group
Intervention type: OTHER
Intervention: acupuncture
Description: Acupuncture points are punctured with needles.
Study NCT06391645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor
Description: intravenously injection
Study NCT06391645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Growth Factor
Description: intravenously injection
Study NCT06215495 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: reduced target volume
Description: Delineate residual tumor(GTVp) and tumor bed(GTVtb) on enhanced contrast CT-MRI(T2 fluid attenuated inversion recovery, T2 FLAIR) fusion images. GTVtb and GTVp are expanded by 1cm to CTV_6000.~The clinical target volume_6000 cGy (CTV_6000) is partially reduced beyond the skull and midline. According to the CT-MRI(T2 FLAIR) fusion images, the edema area that cannot be seen on contrast-enhanced CT and only can be seen on MRI should be included.~If CTV_6000 includes thalamus, basal ganglia, brainstem or motor cortex, dose of these areas will be limited no more than 54Gy
Study NCT06215495 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: EORTC (European organisation for research and treatment of cancer) target volume
Description: delineate according to EORTC guideline
Study NCT06305897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYONOVE (EC14_4osc)
Description: The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
Study NCT06305897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYONOVE (EC+05_1osc)
Description: The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05_1osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
Study NCT06305897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYONOVE (EC+05_2osc)
Description: The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05_2osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
Study NCT06157749 — intervention group
Intervention type: OTHER
Intervention: Gait analysis
Description: It will be carried out on a 10-meter flat surface, with the participant walking at normal walking speed.
Study NCT04770766 — intervention group
Intervention type: OTHER
Intervention: Non-medical practitioners
Description: All observational research activity in each cohort is related to the exposure of non-medical practitioners in the Emergency Department or Urgent Treatment Centre
Study NCT04881903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Intervention for Suicidal Thoughts (MIST)
Description: This is an interpretation bias modification intervention that is designed to target cognitive factors that contribute to suicide risk. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
Study NCT04881903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Intervention for Reducing Anger (MIRA)
Description: This is an interpretation bias modification intervention that is designed to target hostile interpretation bias. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
Study NCT04877080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fast Dual CAR-T Injection
Description: Fast Dual CAR-T injection is a autologous dual CAR-T targeted CD19 and BCMA. A single infusion of CART cells will be administered intravenously.
Study NCT05311501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Non-Surgical periodontal Treatment was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments. Oral Hygiene Instructions (OHI) were provided throughout the experimental period. Local anesthesia was performed only when needed.
Study NCT05084066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated remote ischemic preconditioning
Description: An automated device performs four 5-minute episodes of upper limb ischemia in which the cuff pressure in the experimental group remains at 200 mmHg for 5 minutes, causing and ensuring ischemia. Ischemic episodes alternate with 5-minute reperfusion. The intervention lasts a total of 35 minutes. The participant places the device on his upper arm and presses the Start button, starting the intervention. The intervention takes place at rest in the patient's home environment daily for 28 days. During the first visit to the research center, the research assistant teaches the participant how to use the device. The device measures the patient's blood pressure at the start of the intervention. If the patient's blood pressure is above 200 mmHg, the device will not perform the intervention.
Study NCT05084066 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Simulation of repeated remote ischemic preconditioning (sham)
Description: The automated device simulates the intervention of the experimental group with the difference that the device does not apply pressure to the upper limb and, therefore, no ischemia occurs.